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Purpose: Some recent trials suggest that postoperative adjuvant radiotherapy (RT) 
may be safely omitted after breast-conserving surgery (BCS) for some patients 
with ductal carcinoma in situ (DCIS). In this study, we reviewed clinical outcomes 
of patients with DCIS treated with partial mastectomy (PM) without adjuvant RT. 
Materials and Methods: Medical records of 28 patients (29 breasts) with DCIS 
who were treated with PM, but without RT, between April 1991 and December 
2010 were retrospectively analyzed. Based on established criteria (2.0 cm or less 
in size and no comedonecrosis), 18 patients were treated without RT after PM. 
Seven patients (8 breasts) who did not receive RT due to refusal were also includ-
ed in this study. Three other patients were excluded because data concerning com-
edonecrosis were not available. Results: For the 25 patients included in this study, 
the mean age of the 18 patients who met the criteria was 47.9±6.2 years, and 
47.6±12.7 years for the 7 patients who did not. The mean sizes of the primary tu-
mors were 0.6±0.4 cm and 0.9±0.3 cm, respectively, in these two groups. Among 
these 25 patients (26 breasts) treated without RT, we observed no ipsilateral breast 
tumor recurrence or mortality within a mean follow-up of 84 months. Conclusion: 
Based on this small number of cases, patients with DCIS, who were selected for 
tumor size less than 2 cm and absence of comedonecrosis, may be treated success-
fully with BCS; adjuvant RT may be omitted.
Key Words:   Adjuvant radiaotherapy, ductal carcinoma in situ, mortality, omis-
sion, partial mastectomy, recurrence
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a noninvasive disease with heterogeneous his-
tologic features confined to the ductal lumen of the breast. With increasing use of 
screening mammography and technical advances in diagnostic radiology, the diag-
nosis of DCIS has dramatically increased. Indeed, the incidence of DCIS in Korea 
has increased in the past 10 years, from 4.2% in 1996 to 9.6% in 2006, as com-
pared to 20-25% in the United States.1,2
In the early 1980s, most patients with DCIS were treated with mastectomy, 
which resulted in very low rates (1% to 2%) of local recurrence.3 Since then, how-
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of her own pathologic status and of the option to omit RT 
from the standard regimen for DCIS. The patient was then 
asked to decide whether adjuvant RT should be implement-
ed, in accordance with her preference. Of the 28 patients 
for whom RT was omitted, 8 patients strongly preferred the 
omission, in spite of the presence of comedonecrosis.
In all patients, partial mastectomy was performed with at 
least a 2-cm macroscopic tumor-free margin, and the nega-
tive resection margin status was defined as ‘tumor not touch-
ing ink’ on the frozen section. The size of the DCIS lesion 
was determined from pathology reports and medical records. 
When both data were unavailable, the mammographic ab-
normality was measured on the preoperative mammogram.
Adjuvant hormonal therapy was routinely employed for 
patients who had positive estrogen and/or progesterone re-
ceptor status. After treatment, patients were monitored on a 
regular basis. 
Statistical calculations were performed with SAS (ver-
sion 9.1, Cary, NC, USA). The χ2 test or Fisher’s exact test, 
and the t-test were used to evaluate relationships between 
clinicopathologic variables and comedonecrosis. The recur-
rence and contralateral breast event (CBE) rates were deter-
mined by the Kaplan-Meier method based on the survival 
data. Survival curves were compared using the log-rank 
test. p values <0.05 were considered statistically significant.
 
RESULTS
 
Table 1 lists clinicopathologic characteristics of patients 
treated with PM without adjuvant RT.
For 18 of 25 patients who met target criteria in this study, 
the mean follow-up period was 85.2±60.5 months; and for 
7 patients (8 breasts) who did not meet the criteria, follow-
up was 81±44.4 months (p=0.863). Mean ages in the two 
groups were 47.9±6.2 years and 47.6±12.7 years (p=0.948), 
respectively, and mean sizes of the primary tumor were 
0.6±0.4 cm and 0.9±0.3 cm (p=0.048), respectively. In the 
Van Nuys prognostic classification, 15 (83.3%) of the 18 
patients who met the criteria were group 1. Among 7 pa-
tients who did not meet the criteria, none was group 1, while 
6 patients (75.0%) were group 2 and one (12.5%) was group 
3 (p<0.001). In none of the 25 patients in the study were 
multifocal tumors observed.
One patient had a positive resection margin on her per-
manent evaluation and radiation was omitted due to patient 
refusal, although all margins were negative on frozen sec-
ever, four large randomized controlled trials (RCTs) report-
ed comparable and acceptably low rates of local recurrence 
for patients with DCIS who were treated with breast-con-
serving surgery (BCS) followed by radiation therapy (RT). 
Today, BCS with RT is considered as a standard treatment 
for patients with DCIS,4-9 and in the United States, it is now 
the most common treatment for this form of breast cancer.10
In two retrospective studies, however, patients with small 
lesions that had been widely excised who did not receive 
subsequent adjuvant RT had outcomes comparable to those 
of patients who did receive RT; patients with tumors lack-
ing high-grade features did especially well among those for 
whom RT was omitted.11,12 Although a meta-analysis of the 
previously cited RCTs revealed an approximate 60% reduc-
tion in breast cancer recurrence with the addition of radia-
tion, the additional treatment did not extend survival or re-
duce distant metastases as compared to excision alone. 
Moreover, adjuvant RT was associated with a 1.53-fold in-
crease in risk for contralateral breast cancer.13 In this set-
ting, the use of adjuvant RT presents a dilemma. If survival 
cannot be extended, prevention of local recurrence becomes 
the major treatment goal. Although RT may reduce local re-
currence, it increases morbidity and inconvenience.14 Ac-
cordingly, there is intensive debate concerning whether to 
omit adjuvant RT for some patients with DCIS.
In this retrospective study, at our single institution, we in-
vestigated the long-term outcomes of patients with DCIS 
treated with partial mastectomy (PM) without adjuvant RT.
MATERIALS AND METHODS
　　　
Patients diagnosed with DCIS and treated with PM without 
RT between April 1991 and December 2010 at the Gang-
nam Severance Hospital in Korea were identified, and data 
were extracted from their records retrospectively. The inter-
nal review board at this institution waived the informed 
consent requirement for this retrospective study.
Among the 2933 patients (3062 breasts) diagnosed in this 
period, 302 patients (10.3%) with DCIS were treated. Of 
these patients, 87 (28.8%) were treated with PM. Fifty-one 
patients (58.6%) were treated with RT, and 28 patients 
(32.2%) were treated without RT. Eight patients (9.2%) were 
excluded from this study because data regarding RT were 
not available. Eligibility criteria for omission of adjuvant 
RT after PM were 1) DCIS lesions measuring ≤2.0 cm; and 
2) absence of comedonecrosis. Each patient was informed 
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groups did not differ statistically (p=0.186) (Fig. 2).
DISCUSSION
Patients with invasive or in situ breast carcinoma frequently 
tion. Adjuvant hormone therapy was administered to 13 pa-
tients (76.5%).
No ipsilateral breast tumor recurrences (IBTR), distant 
metastases, or deaths occurred in either group (Fig. 1). A 
CBE developed in one patient (12.5%) treated without RT 
among the patients with comedonecrosis, but the two 
Table 1. Clinicopathologic Characteristics of 26 Breasts (25 Patients) Treated with Partial Mastectomy without Adjuvant Ra-
diotherapy for Ductal Carcinoma In Situ
Characteristic
Accordance with criteria 
(absence of comedonecrosis)
Non-accordance with criteria 
(presence of comedonecrosis) p value
Number % Number %
Total number of breasts treated 18 69.2 8   30.8 -
Follow-up period, months, mean±SD   85.2±60.5    81±44.4   0.863
Age, mean±SD 47.9±6.2 47.6±12.7   0.948
    <50 yrs 12   66.7 5   62.5 >0.999
    ≥50 yrs   6   33.3 3   37.5
Tumor size, centimeters, mean±SD   0.6±0.4 0.9±0.3   0.048
Grade
    Non-high 15   83.3 6   75.0   0.318
    High   0  0 1   12.5
    Unknown   3   16.7 1   12.5
Van Nuys Group classification
    1 15   83.3 0  0 <0.001
    2   0  0 6   75.0
    3   0  0 1   12.5
    Unknown   3   16.7 1   12.5
Multifocality
    Negative 18 100.0 8 100.0 -
    Positive   0  0 0  0
    Unknown   0  0 0  0
Estrogen receptor
    Positive 10   55.6 7   87.5 -
    Negative   0  0 0  0
    Unknown   8   44.4 1   12.5
HER2*
    Negative   9   50.0 4   50.0  0.25
    Positive   1     5.6 3   37.5
    Unknown   8   44.4 1   12.5
p53*
    Negative   9   50.0 1   12.5   0.046
    Positive   0  0 2   25.0
    Unknown   9   50.0 5   62.5
Resection margin
    Negative 17   94.4 8 100.0 >0.999
    Positive   1     5.6 0  0
Hormone therapy
    Yes 14   77.8 7   87.5 >0.999
    No   3   16.6 1   12.5
    Unknown   1     5.6 0  0
HER2, human epidermal growth factor receptor 2.
*HER2 and p53 were tested by immunohistochemical staining (IHC). HER2-positive status was confirmed if the IHC staining showed a positive result in 
three tests or if fluorescence in situ hybridization showed positive gene amplification for three non-positive IHC results.
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reported that tumor size was positively associated with 
IBTR; however, many of the relationships tested in these 
studies were not statistically significant. The studies gener-
ally classified tumors of less than 20 mm as small, although 
some defined small as less than 5 mm.
Surgical margin is an another important risk factor for re-
currence. In early 1990, Veronesi, et al.24 reported that tumor 
excision with 2-3 cm of normal tissue around the infiltrat-
ing tumor resulted in a lower local recurrence rate than ex-
cision with 1 cm of normal tissue. Silverstein, et al.11 suggest-
ed that for patients with DCIS treated with BCS, excellent 
control of local recurrence can be achieved without radia-
tion therapy if the tumor is excised with a margin of at least 
10 mm, regardless of nuclear grade, the presence of come-
donecrosis, or tumor size.
When we initially designed this study, no specific criteria 
for omission of RT, analogous to the Van Nuys DCIS Patho-
logic Classification or the VNPI,16 had yet been proposed. 
Therefore, we postulated that the absence of comedonecro-
sis, a tumor size less than 2 cm, and a sufficiently large ex-
cision margin would provide valid criteria for the omission 
of adjuvant RT after PM in DCIS.
The results of several prospective trials show that adju-
vant RT after BCS significantly reduces the risk of local re-
currence in DCIS. Nevertheless, in contrast to data for pa-
tients with invasive breast cancer, who show a significant 
survival benefit from RT after BCS,25,26 none of these ran-
domized trials show a benefit for patients with DCIS in 
terms of distant metastases, breast cancer-specific survival, 
or overall survival.4-9 Moreover, although the risk of com-
plications after adjuvant RT is small,27 such risk must be 
considered to determine the subsets of patients with DCIS 
most likely to benefit from RT.28 Gilleard, et al.29 empha-
report that concerns regarding disease recurrence and the 
side effects of radiation influenced their treatment deci-
sions, and that these concerns led them to favor mastecto-
my.15 Important prognostic factors in local recurrence for 
patients with DCIS treated with BCS include age, popula-
tion, tumor size, histologic grade, comedonecrosis, margin 
width and the Van Nuys Prognostic Index (VNPI).16-19 Kim, 
et al.20 showed that younger age at diagnosis and the omis-
sion of adjuvant RT independently predict recurrence in 
Korean patients with DCIS who are treated with BCS.
On the other hands, Punglia, et al.21 have recently showed 
that patient age and preference should be considered when 
making the decision to add or not to add radiation for DCIS.
Among these factors, Schwartz, et al.22,23 and Fisher, et 
al.17 emphasized the significance of comedonecrosis in pre-
dicting local recurrence. Schwartz, et al. determined that pa-
tients with small non-comedo lesions with uninvolved mar-
gins are not likely to receive any significant benefits from 
RT, and that patients with DCIS having calcifications rang-
ing from 2.0 to 2.5 cm in diameter may, safely choose to 
omit RT with continual surveillance. Based on the results 
from the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) protocol B-24, which included 1456 pa-
tients with 10.5 years of follow-up, Fisher, et al. concluded 
that ductal comedonecrosis, micropapillary histologic tu-
mor type, and multifocality predict IBTR strongly and in-
dependently, and that data from the NSABP B-17, which 
included 2079 patients, identified comedonecrosis as a sim-
ple strong predictor for IBTR.
Gilleard, et al.18 analyzed 5 randomized controlled clini-
cal trials and 64 observational studies published from 1970 
to 2009 to test the associations of patient and tumor charac-
teristics with clinical outcomes in women with DCIS, and 
Fig. 1. Disease-free survival for local recurrence in patients with ductal 
carcinoma in situ treated with partial mastectomy without radiotherapy.
Fig. 2. Disease-free survival for contralateral breast events according to 
comedo-necrosis in patients with ductal carcinoma in situ treated with 
partial mastectomy without radiotherapy.
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be interpreted to mean that small lesion size (less than 1.5 
cm) and/or the absence of comedonecrosis, combined with 
a relatively large resection margin, constitute acceptable 
criteria for omission of adjuvant RT following PM for DCIS. 
This set of criteria may have an advantage over the VNPI 
for its relative simplicity, if validated in further trials.
This study is limited first and most importantly, by the 
small number of subjects and events included in the analy-
sis, and the use of a retrospective design rather than a pro-
spective randomized design, which would greatly reduce 
selection bias. As Hughes, et al. point out, a more favorable 
tumor size among study subjects than specified by inclu-
sion criteria (mean 0.60 cm without comedonecrosis, and 
0.95 cm with comedonecrosis in our study) may introduce 
a positive bias for outcome in the subset of patients for 
whom RT was omitted. Although events affecting outcome 
may increase after 7 years, we would need to follow a larg-
er patient sample for 10 years or more to determine this. In 
addition, a margin of 2 cm or more may be somewhat ex-
cessive to maintain an aesthetic contour, which for some 
patients may be as important to consider as the oncologic 
outcome.
In conclusion, based on this study, we propose a relative-
ly simple set of criteria to determine whether adjuvant RT 
may be safely omitted after PM for some Korean patients 
with DCIS. These criteria include the absence of comedo-
necrosis, lesion size 2 cm or less, and an excision margin 
greater than 2 cm. Even in the presence of comedonecrosis, 
omission of adjuvant RT may be considered for patients 
with lesions of 1.5 cm or less, if a wide excision margin 
was achieved. To verify the safety of these criteria and the 
acceptability of outcome, a large prospective randomized 
trial is needed. Future investigations must also address the 
molecular aspects of this approach to treat DCIS, so as to 
predict outcome more precisely and optimize the treatment 
for each individual.
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